|
Study of Nivolumab plus Ipilimumab plus Sargramostim Versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma (EA6141) |
II |
|
|
Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (18264) |
III |
|
|
Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer (GY018) |
III |
|
|
Study of pembrolizumab with or without lenvatinib to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 population with recurrent or metastatic head and neck squamous cell carcinoma(LEAP010) |
|
|
|
Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) Participants (19020) |
III |
|
|
Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma (EA2187) |
II |
|
|
Study of Relacorilant in Combination with NabPaclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (CORT125134-553) |
II |
|
|
Study of RRx001 administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer (RRx-001-33) |
III |
|
|
Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNGMAP Sub-Study) (S1900A) |
II |
|
|
Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (16238) |
III |
|
|
Study of the Highly-selective RET Inhibitor, BLU667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-6671101) 18164 |
I |
|
|
Study of the Saftey of TTX-030 as a single agent and in Combination with Pembrolizumab or Chemotherapy in Patients with Lymphoma or Solid Tumor Malignancies (TTX-030-001) |
I |
|
|
Study of the Saftey of TTX-030 as a single agent and in Combination with Pembrolizumab or Chemotherapy in Patients with Lymphoma or Solid Tumor Malignancies (TTX-030-001) |
I |
|
|
Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas (A051701) |
II |
|
|
Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas (A051701) |
|
|
|
Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC) |
II |
|
|
Study on Physical Activity’s Relationship with Cancer and Cognition (SPARCC) |
|
|
|
Study Testing the Addition of Nivolumab Pre and Post Nephrectomy in Patients with Renal Cell Carcinoma (EA8143) |
III |
|
|
Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV- 368 plus Tilsotolimod in Subjects with Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma study (Abbvie M19-894) |
I |
|
|
Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)(7465-CL-202) |
II |
|
|
Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)(7465-CL-202) |
II |
|
|
Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)(7465-CL-202) |
II |
|
|
Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)(7465-CL-202) |
II |
|
|
Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)(7465-CL-202) |
II |
|
|
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)19079 |
II |
|
